BioCentriq
David Smith is a seasoned professional in the field of regenerative medicine with extensive experience in development and technical operations. Currently serving as Vice President of Development at BioCentriq since January 2023, David previously held the position of Vice President of Technical Operations at Ori Biotech from October 2020 to December 2022. Earlier roles include Director of Research and Development at Minaris Regenerative Medicine and Hitachi Chemical Advanced Therapeutics Solutions, where David focused on innovation and engineering within cell therapy manufacturing processes. David's educational background includes a Ph.D. in Regenerative Medicine from Loughborough University and an MEng in Biochemical Engineering from the University of Bath. Notable research experiences include the development of a live cell imaging platform and process analytical technologies for cell therapy.
BioCentriq
Established in 2019, BioCentriq is a full-service, New Jersey-based CDMO for cell and gene therapy, focusing on all stages of process development and clinical manufacturing. With over 90 scientists, engineers, analysts, and manufacturing specialists, we have the quality systems and infrastructure required to support the release of both autologous and allogeneic drug products. BioCentriq also specializes in viral vector process development and manufacturing with expertise in a variety of cell and vector types. Our 35,000 square feet of facilities includes four, soon to be five, ISO-7 certified GMP manufacturing suites, a fully equipped process development laboratory, quality control and analytical method development laboratories, and training facilities. We also operate the only McKinsey-owned Innovation & Learning Center designed to explore the application of industry 4.0, digital and lean manufacturing disciplines to life sciences.